



DEPARTMENT OF DEFENSE
ARMED FORCES EPIDEMIOLOGICAL BOARD
5109 LEESBURG PIKE
FALLS CHURCH, VA 22041-3258



AFEB (15-1a) 94-7

03 August 1994

MEMORANDUM FOR THE ASSISTANT SECRETARY OF DEFENSE (HEALTH AFFAIRS)

SUBJECT: Biological Warfare Vaccines

In accordance with DoD Directive 6205.3, the Armed Forces Epidemiological Board (AFEB) met on 3 August 1994 to review two vaccines available to protect against validated biological warfare threat agents and makes the following recommendations:

- a. THE LICENSED ANTHRAX VACCINE IS SUITABLE FOR USE IN PERSONNEL ASSIGNED, PRE-DESIGNATED OR SCHEDULED FOR DEPLOYMENT TO AREAS WITH A VALIDATED HIGH THREAT UNDER ITS APPROVED INSTRUCTIONS.
- b. THE INVESTIGATIONAL BOTULINUM TOXOID VACCINE IS SUITABLE FOR USE UNDER THE CURRENT PROTOCOL IN PERSONNEL WITH RISK AS DEFINED ABOVE. THE BOARD STRONGLY ENCOURAGES PURSUIT OF FDA APPROVAL OF THIS PRODUCT.

FOR THE ARMED FORCES EPIDEMIOLOGICAL BOARD:

LEWIS H. KULLER, M.D., DrPH
President, AFEB

MICHAEL R. PETERSON, DVM, MPH, DrPH
Colonel, USAF, BSC
Executive Secretary

CF: CO, USAMRDALC



DEPARTMENT OF THE ARMY
OFFICE OF THE SURGEON GENERAL
5109 LEESBURG PIKE
FALLS CHURCH, VA 22041-3258



REPLY TO
ATTENTION OF
DASG-RDZ (40-562)

MEMORANDUM FOR ARMED FORCES EPIDEMIOLOGICAL BOARD (AFEB)

SUBJECT: Special Meeting of the AFEB

1. References:

a. Meeting, AFEB, 8 Jul 94, subject: Program Review.

b. Department of Defense (DoD) Directive 6205.3, DoD Immunization Program for Biological Warfare Defense, 26 Nov 93.

2. The AFEB met 8 Jul 94 and agreed to conduct a subgroup meeting to support the implementation of the DoD Immunization Program for Biological Warfare Defense.

3. Request:

a. The AFEB meet 3 Aug 94.

b. Review specific biological defense immunization recommendations.

c. The Chair of the AFEB identify vaccines available to protect against biological threat agents designated by the Chairman of the Joint Chiefs of Staff and recommend appropriate immunization protocols.

4. Point of contact for this action is MAJ William Klenke, DASG-HCO, DSN 289-8185 or commercial (703) 756-8185.

FOR THE SURGEON GENERAL:


RUSS ZAITCHUK
Brigadier General, MC
Assistant Surgeon General

CF:
SGPS-PSP
JPO-BD
SGRD-PLD
DASG-HCO



**DEPARTMENT OF DEFENSE
ARMED FORCES EPIDEMIOLOGICAL BOARD
5109 LEESBURG PIKE
FALLS CHURCH, VA 22041-3258**



REPLY TO
ATTENTION OF

AFEB (15-1a)

08 November 1996

MEMORANDUM FOR THE ASSISTANT SECRETARY OF DEFENSE (HEALTH AFFAIRS)


SUBJECT: Armed Forces Epidemiological Board (AFEB) Recommendation for Biological Warfare (BW) Vaccines


1. In accordance with DoD Directive 6205.3, DoD Immunization Program for Biological Warfare Defense, the AFEB Disease Control Committee met on 31 October 1996 at USAMRIID to review vaccines available to protect against the validated BW threat agents.
2. The AFEB makes the following comments and recommendations as a result of that meeting:
 - a) The AFEB endorses the proposed DoD anthrax vaccine implementation plan under the current vaccine protocol. The committee recommends that DoD aggressively pursue clinical investigations necessary to resolve questions about an accelerated anthrax vaccine schedule.
 - b) The investigational botulinum toxoid vaccine is suitable for use under the current protocol in personnel with risk of exposure to BW agents. The AFEB strongly recommends that DoD continue to pursue investigations and discussions with FDA to facilitate licensure of this vaccine.
 - c) Because of certain characteristics of staphylococcal enterotoxin B (SEB) and tularemia which make them potentially effective BW agents, the AFEB recommends that DoD continue advanced development of the SEB vaccine as rapidly as possible and aggressively pursue licensure of the IND tularemia vaccine.
 - d) Because of the fact that Venezuelan equine encephalitis (VEE) is both an endemic threat to U.S. forces in certain parts of the world and a potential BW threat, the AFEB recommends that DoD continue advanced development of the new VEE vaccine.
 - e) The AFEB highly recommends discussions between DoD and FDA on issues regarding licensure of vaccines of significance against BW agents. A joint meeting of the AFEB with DoD and FDA should be considered. Among the issues that should be discussed are: 1) development of combination vaccine products and immunization schedules to facilitate delivery of vaccines to military personnel; 2) acceptance of surrogate marker data for BW vaccines.
 - f) When vaccines are not effective or available against validated BW agents, the AFEB recommends a study of medical resources necessary for rapid deployment of troops to high risk areas, including availability of appropriate chemoprophylaxis where indicated.


AFEB (15-1a)

08 November 1996

SUBJECT: Armed Forces Epidemiological Board (AFEB) Recommendation for Biological Warfare (BW) Vaccines


GERALD F. FLETCHER, M.D.
President, AFEB


WILLIAM SCHAFFNER, II, M.D.
Chairman, Disease Control Committee


VICKY L. FOGELMAN, COL, USAF, BSC
AFEB Executive Secretary

CF:
The Surgeon General, Army